Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH Z FORSTOT

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1144323023
CMS profile
233505
Location
BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,170.76

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,972.76 149
Education $198.00 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH Z FORSTOT

NPI 1144323023 · CMS profile ID 233505

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144323023?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH Z FORSTOT, NPI 1144323023, CMS profile ID 233505. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144323023?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOSEPH Z FORSTOT, NPI 1144323023, CMS profile ID 233505. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144323023?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOSEPH Z FORSTOT, NPI 1144323023, CMS profile ID 233505, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1144323023?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $3,170.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $17.2504/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175027396 CMS
Janssen Biotech, Inc. $0.3004/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175031640 CMS
PFIZER INC. $16.4204/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229050467 CMS
ABBVIE INC. $14.7904/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871589 CMS
ABBVIE INC. $0.9104/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871591 CMS
ABBVIE INC. $0.1104/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871593 CMS
SOBI, INC $21.0004/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240233656 CMS
ABBVIE INC. $14.9704/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871587 CMS
ABBVIE INC. $20.3304/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871585 CMS
Novartis Pharmaceuticals Corporation $17.1804/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200289870 CMS
Janssen Biotech, Inc. $19.0104/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175026190 CMS
Janssen Biotech, Inc. $16.2003/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175031121 CMS
ABBVIE INC. $20.5603/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871583 CMS
E.R. Squibb & Sons, L.L.C. $0.5803/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184808583 CMS
E.R. Squibb & Sons, L.L.C. $20.8103/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184808585 CMS
Amgen Inc. $19.9403/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228350998 CMS
Novartis Pharmaceuticals Corporation $8.0103/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200289872 CMS
PFIZER INC. $16.3003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231436256 CMS
Radius Health, Inc. $31.3603/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249513289 CMS
Novartis Pharmaceuticals Corporation $22.1103/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200289868 CMS
Novartis Pharmaceuticals Corporation $26.4603/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200289866 CMS
ABBVIE INC. $34.5303/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871581 CMS
Genentech USA, Inc. $19.7303/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211527942 CMS
GlaxoSmithKline, LLC. $17.9503/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190357890 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.9103/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222852324 CMS
ABBVIE INC. $16.4303/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871579 CMS
Aurinia Pharma U.S., Inc. $24.1303/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249411927 CMS
E.R. Squibb & Sons, L.L.C. $1.4402/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184808575 CMS
E.R. Squibb & Sons, L.L.C. $19.9702/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184808579 CMS
Mallinckrodt Hospital Products Inc. $37.7702/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211965198 CMS
PFIZER INC. $17.1902/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231562202 CMS
GENZYME CORPORATION $27.6102/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233196836 CMS
Novartis Pharmaceuticals Corporation $17.1502/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200289884 CMS
UCB, Inc. $37.1402/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224354285 CMS
Janssen Biotech, Inc. $24.9102/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175033315 CMS
ABBVIE INC. $24.4002/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871577 CMS
Amgen Inc. $18.1402/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228350988 CMS
Amgen Inc. $24.7102/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228351020 CMS
Janssen Biotech, Inc. $24.1901/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175030709 CMS
PFIZER INC. $19.6601/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231115490 CMS
ABBVIE INC. $26.2601/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201871575 CMS
Novartis Pharmaceuticals Corporation $17.6601/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200289882 CMS
Amgen Inc. $18.6601/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228351018 CMS
Amgen Inc. $8.8901/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227074860 CMS
E.R. Squibb & Sons, L.L.C. $29.6601/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184808547 CMS
E.R. Squibb & Sons, L.L.C. $0.6201/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184808549 CMS
Alexion Pharmaceuticals, Inc. $26.2101/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202919288 CMS
GlaxoSmithKline, LLC. $20.2501/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191139748 CMS
Janssen Biotech, Inc. $20.7001/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175029554 CMS
UCB, Inc. $22.3201/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224354283 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,915.08 188
PY2020 $635.50 39
PY2021 $2,292.87 154
PY2022 $2,784.76 157
PY2023 $2,935.77 145
PY2024 $3,833.15 200
PY2025 $3,170.76 151

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $98,503.55 26
PY2024 Principal investigator $127,936.30 29
PY2023 Principal investigator $248,268.68 39
PY2022 Principal investigator $189,820.29 31
PY2021 Principal investigator $126,690.30 27
PY2020 Recipient $1,508.81 1
PY2020 Principal investigator $124,704.23 38
PY2019 Principal investigator $263,203.20 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,062.95 11/04/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520193
Principal investigator 1 ABBVIE INC. $2,543.83 11/04/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202520195
Principal investigator 1 ABBVIE INC. $12,300.43 10/23/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202518215
Principal investigator 1 ABBVIE INC. $2,488.75 10/09/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202513895
Principal investigator 1 ABBVIE INC. $6,940.00 09/18/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202511592
Principal investigator 1 ABBVIE INC. $7,880.00 09/04/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202509916
Principal investigator 1 ABBVIE INC. $2,303.80 09/03/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202508302
Principal investigator 1 ABBVIE INC. $2,284.63 08/05/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202502086
Principal investigator 1 ABBVIE INC. $4,741.25 08/05/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202502088
Principal investigator 1 ABBVIE INC. $7,270.50 07/02/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494445
Principal investigator 1 ABBVIE INC. $2,252.50 07/02/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494447
Principal investigator 1 ABBVIE INC. $890.00 06/11/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202490863
Principal investigator 1 ABBVIE INC. $380.00 06/03/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488207
Principal investigator 1 ABBVIE INC. $1,847.50 06/03/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488281
Principal investigator 1 ABBVIE INC. $2,968.15 05/06/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481453
Principal investigator 1 ABBVIE INC. $2,348.35 05/06/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481455
Principal investigator 1 ABBVIE INC. $1,978.18 05/06/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202481457
Principal investigator 1 ABBVIE INC. $4,880.30 04/03/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202470885
Principal investigator 1 ABBVIE INC. $6,354.50 04/03/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202470889
Principal investigator 1 ABBVIE INC. $2,348.35 03/06/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202456478
Principal investigator 1 ABBVIE INC. $1,120.65 03/06/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202456481
Principal investigator 1 ABBVIE INC. $302.20 03/06/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202456485
Principal investigator 1 ABBVIE INC. $4,763.80 02/05/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER INC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202443934
Principal investigator 1 ABBVIE INC. $4,739.90 02/05/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202443942
Principal investigator 1 ABBVIE INC. $1,982.43 02/05/2025 Non-covered Recipient Entity
RASF-CLINICAL RESEARCH CENTER
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202443945
Principal investigator 1 ABBVIE INC. $2,530.60 01/02/2025 Non-covered Recipient Entity
RASF CLINICAL RESEARCH INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202433443